



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	International Journal of Biochemistry Research & Review
Manuscript Number:	Ms_IJBCRR_20709
Title of the Manuscript:	Effect of Carboplatin and Methotrexate on Lipid Levels in the Plasma Membrane of MCF-7 Cells and their Association with Cell Motility
Type of the Article	Original Research Article

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
The authors' response (see below) was not found in materials and methods of the revised manuscript: "We re-mentioned in materials and methods that MTT assays were conducted first in the presence of fetal bovine serum and no effect on cells was obtained in the presence of either drug added. Hence, experiments were carried later in the absence of FBS where effect of drug was noticed."	Again, I would like by re-thanking you for taking the time to re-revise our manuscript. Re-corrected.
The following were still not revised (see revised manuscript for ER (Line 166)and BSA (Line 176)): Abbreviated terms should be expressed in full when used for the very first time.	ER was corrected but BSA abbreviation is added.
The following were still not revised (see revised manuscript for Lines 216-217): Line 214: "the standard deviation" should be corrected as "standard deviation"	On line 116, the word "the" was removed On line 214, I must add the word "the" as I am specifying the statistical package we used.
The authors did not answer the following comments: (i) It is essential for the authors to compare the 24 h IC50 of carboplatin obtained in the present study to those of the previous studies against the <u>same cell line (i.e. MCF7)</u>. The authors have compared their results to cell lines of different cell types: human urinary bladder cancer cell line (TCC), leukemic cell lines (CEM, HL60, U937 and K562), human ovarian cancer cell lines (A721, A90, A286, AI, and A121A), epithelial ovarian cancer cell lines (SKOV-3 and OVCAR-3) ovarian cancer cells BG-1 (see revised manuscript for Lines 316-324). (ii) It is also essential for the authors to disclose the duration of treatment for the results cited from previous studies. The authors need to <u>specify</u> it in each study they compared their results to. General statement like "Most treatments were done for 24 hours" is not sufficient.	IC₅₀ for both drugs obtained by other researchers were added along with their time of incubation and compared with our results. We prefer to determine effect of drugs after a maximum of 24 hrs to eliminate possibility of cell overgrowth or possible dehydration/condensation of media in 96 well plates especially that media volume used is only 100 µl. These artifacts has been seen upon prolonged incubation for more than 48 hrs, hence we avoid longer incubation.



SDI FINAL EVALUATION FORM 1.1

The authors did not answer the following comment (see revised manuscript for Lines 328-330): It is essential for the authors to compare the 24 h IC50 of methotrexate obtained in the present study to those of the previous studies against the <u>same cell line (i.e. MCF7)</u>. The statement in the text is too general: “MTX has been actively used in the treatment in several malignancies, including head and neck, breast, and bone tumours, leukemias and lymphomas”	
The authors did not answer the following comment: Lines 338-339 (original manuscript): It is essential for the authors to justify the basis of claiming “the drugs could have been chelated by the proteins found in the FBS”. This is <u>contradicting</u> to Line 138 whereby the authors stated that the cells were being serum starved during treatment. The statement “In discussion, we tried to put the different plausible reasons why drugs may not inhibit cell growth.” still did not explain the contradictory claim.	Dear reviewer, I clarified previously that we did not observe any cytotoxic effect on MCF-7 cells when drugs was mixed with media containing fetal bovine serum (FBS). Cytotoxic effect of the drug was seen after we eliminated the FBS from media before treatment. Hence, in our discussion, we were giving different suggestions why drugs may not show cytotoxic effect on cells in general. The chelation effect is not applicable in our case as treatment was done in absence of FBS and we have eliminated this possibility in our discussion. So, no contradiction. I have included in results a statement indicating that both drugs had no effect when mixed with FBS containing media.
The authors did not answer the following comment (see line 6 of revised manuscript): For full generic name, carboplatin and methotrexate <u>should be presented as small cap</u> throughout text and captions.	Notion corrected.
The authors did not answer the following comment: Tables: The decimal place of the data should be consistent.	Decimals were re-corrected in tables.